A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer Masahiro TabataKatsuyuki KiuraMitsune Tanimoto Original Article 29 March 2007 Pages: 1 - 6
Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin Zeljko M. PrijovichYu-Lin LeuSteve R. Roffler Original Article 16 September 2006 Pages: 7 - 17
Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment Angelo MancinelliS. D’IddioM. Calvani Original Article 20 September 2006 Pages: 19 - 26
Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site Pascal SèveTony ReimanJohn R. Mackey Original Article 22 September 2006 Pages: 27 - 34
Inhibition of NF-κB-mediated transcription and induction of apoptosis by melampolides and repandolides Guoyi MaShabana I. KhanDavid S. Pasco Original Article 06 December 2006 Pages: 35 - 43
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models Li-mou ZhengZujin LiIvan King Original Article 26 January 2007 Pages: 45 - 51
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study Masahiro TabataToshiyuki Kozukifor the Okayama Lung Cancer Study Group Original Article 29 September 2006 Pages: 53 - 59
Phase II trial of 10-EDAM in the treatment of metastatic breast cancer Garth A. BeinartAna M. Gonzalez-AnguloG. N. Hortobagyi Original Article 29 September 2006 Pages: 61 - 67
Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells Chong-Zhi WangXiaoji LuoChun-Su Yuan Original Article 29 September 2006 Pages: 69 - 79
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC) Roger B. CohenCorey J. LangerDiane Healey Original Article 10 October 2006 Pages: 81 - 89
Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line Jason ZastreMalathi AnanthaMarcel Bally Original Article 29 September 2006 Pages: 91 - 102
The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line Wei-Ciao WuJenn-Ren HsiaoBu-Miin Huang Original Article 10 October 2006 Pages: 103 - 111
The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men Martijn TriesscheijnMarjan RuevekampFiona A. Stewart Original Article 29 September 2006 Pages: 113 - 122
Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer G. P. StathopoulosN. A. MalamosD. Skarlos Original Article 17 November 2006 Pages: 123 - 128
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study Jong Gwang KimSang Kyun SohnSuk Joong Oh Original Article 04 April 2007 Pages: 129 - 134
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma Monika K. KrzyzanowskaIan F. TannockGeorg A. Bjarnason Clinical Trial Report 29 September 2006 Pages: 135 - 141
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial D. BinderH. SchweisfurthT. Beinert Clinical Trial Report 10 October 2006 Pages: 143 - 150